Drug Profile
DE 096
Alternative Names: DE-096Latest Information Update: 29 May 2018
Price :
$50
*
At a glance
- Originator Santen Pharmaceutical
- Class Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic macular oedema; Rheumatoid arthritis
Most Recent Events
- 10 May 2005 Phase-II clinical trials in Diabetic macular oedema in Japan (PO)
- 10 May 2005 Phase-II clinical trials in Rheumatoid arthritis in Japan (PO)
- 31 Dec 2003 DE 096 is available for licensing external to Japan (http://www.santen.co.jp)